Health technology assessment of long-acting erythropoiesis-stimulating agents for the treatment of renal anemia in China
- 1Department of Pharmacy, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University , , ,
Abstract
Introduction: Renal anemia is a common complication of chronic kidney disease (CKD) and is associated with increased cardiovascular morbidity and mortality and reduced quality of life. Long-acting erythropoiesis-stimulating agents (ESAs) offer advantages in dosing convenience and adherence, but a comprehensive multidimensional evaluation comparing these agents within the Chinese healthcare context is lacking.
Objective: The aim of this study was to conduct a multidimensional quantitative evaluation of long-acting ESAs and provide a reference for drug selection and rational clinical use in medical institutions.
Methods: Based on the method recommended in the Rapid Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (Third Edition), three long-acting ESAs were evaluated in five dimensions, namely, efficacy (28 points), safety (27 points), pharmaceutical properties (27 points), economy (10 points), and other attributes (8 points).
Results: The final assessment scores were 80.39 points for the continuous erythropoietin receptor activator (CERA), 73.04 points for pegmolesatide, and 71.70 points for darbepoetin alfa, in descending order. CERA achieved the highest scores in safety and other attributes, darbepoetin alfa ranked first in economy, and pegmolesatide performed best in pharmaceutical properties.
Conclusion: According to the scoring results, CERA, pegmolesatide, and darbepoetin alfa all exceeded the guideline-defined threshold for strong recommendation (>70 points) and can be included in the list of strongly recommended drugs for medical institutions. This study provides a scientific, reasonable, and safe basis for medical institutions to select long-acting ESAs.
Related
- Comparing Erythropoietin, Darbepoetin and No Erythropoiesis-Stimulating Agent Treatment in Preventing Anemia of Prematurity: A Multi-Center Retrospective Study
- Early erythropoiesis‐stimulating agents in preterm or low‐birthweight infants
- Elevated Anti-Cytomegalovirus IgG Levels Are Associated with Higher Erythropoiesis-Stimulating Agent Dose in Transplant-Listed Patients with End-Stage Kidney Disease
- Recombinant follicle‐stimulating hormone (rFSH) versus other recombinant or urinary gonadotropins for ovarian stimulation in assisted reproductive technology cycles
- Three pillars for digital health assessment in LMICs: a mini review of technology benchmarking, digital health literacy, and social media listening
BibTeX
@article{wang2026health,
title = {{Health technology assessment of long-acting erythropoiesis-stimulating agents for the treatment of renal anemia in China}},
author = {Xinwen Wang and Huiling Li and Yazhuo Zhang and Yinyin Duan},
journal = {Frontiers in pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1878826},
url = {https://europepmc.org/article/PMC/PMC13672644},
note = {CC BY},
}
RIS
TY - JOUR
TI - Health technology assessment of long-acting erythropoiesis-stimulating agents for the treatment of renal anemia in China
AU - Xinwen Wang
AU - Huiling Li
AU - Yazhuo Zhang
AU - Yinyin Duan
PY - 2026
DA - 2026/10/02
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1878826
UR - https://europepmc.org/article/PMC/PMC13672644
AB - Introduction: Renal anemia is a common complication of chronic kidney disease (CKD) and is associated with increased cardiovascular morbidity and mortality and reduced quality of life. Long-acting erythropoiesis-stimulating agents (ESAs) offer advantages in dosing convenience and adherence, but a comprehensive multidimensional evaluation comparing these agents within the Chinese healthcare context is lacking. Objective: The aim of this study was to conduct a multidimensional quantitative evaluation of long-acting ESAs and provide a reference for drug selection and rational clinical use in medical institutions. Methods: Based on the method recommended in the Rapid Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (Third Edition), three long-acting ESAs were evaluated in five dimensions, namely, efficacy (28 points), safety (27 points), pharmaceutical properties (27 points), economy (10 points), and other attributes (8 points). Results: The final assessment scores were 80.39 points for the continuous erythropoietin receptor activator (CERA), 73.04 points for pegmolesatide, and 71.70 points for darbepoetin alfa, in descending order. CERA achieved the highest scores in safety and other attributes, darbepoetin alfa ranked first in economy, and pegmolesatide performed best in pharmaceutical properties. Conclusion: According to the scoring results, CERA, pegmolesatide, and darbepoetin alfa all exceeded the guideline-defined threshold for strong recommendation (>70 points) and can be included in the list of strongly recommended drugs for medical institutions. This study provides a scientific, reasonable, and safe basis for medical institutions to select long-acting ESAs.
SN - 1663-9812
ER -